{
    "organizations": [],
    "uuid": "0381b553d4f5b50e7a803976d9869aa0fea60d50",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alnylam-retains-global-rights-to-l/brief-alnylam-retains-global-rights-to-lumasiran-investigational-rnai-therapeutic-for-treatment-of-primary-hyperoxaluria-type-1-idUSFWN1QU0PN",
    "ord_in_thread": 0,
    "title": "BRIEF-Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 12, 2018 / 11:10 AM / in 8 minutes BRIEF-Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1 Reuters Staff 1 Min Read March 12 (Reuters) - Alnylam Pharmaceuticals Inc: * ALNYLAM RETAINS GLOBAL RIGHTS TO LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) * ALNYLAM PHARMACEUTICALS INC - ‍COMPANY PLANS TO ACCELERATE DEVELOPMENT WITH PHASE 3 START IN LATE 2018​ * ALNYLAM PHARMACEUTICALS INC - ‍LUMASIRAN GRANTED BREAKTHROUGH THERAPY DESIGNATION BY UNITED STATES FOOD AND DRUG ADMINISTRATION​ * ALNYLAM PHARMACEUTICALS INC - ‍SANOFI GENZYME HAS DECLINED ITS OPT-IN FOR DEVELOPMENT AND COMMERCIALIZATION OF LUMASIRAN​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-12T13:08:00.000+02:00",
    "crawled": "2018-03-12T13:21:30.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "minute",
        "retains",
        "global",
        "right",
        "lumasiran",
        "investigational",
        "rnai",
        "therapeutic",
        "treatment",
        "primary",
        "hyperoxaluria",
        "type",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "alnylam",
        "pharmaceutical",
        "inc",
        "alnylam",
        "retains",
        "global",
        "right",
        "lumasiran",
        "investigational",
        "rnai",
        "therapeutic",
        "treatment",
        "primary",
        "hyperoxaluria",
        "type",
        "ph1",
        "alnylam",
        "pharmaceutical",
        "inc",
        "plan",
        "accelerate",
        "development",
        "phase",
        "start",
        "late",
        "alnylam",
        "pharmaceutical",
        "inc",
        "granted",
        "breakthrough",
        "therapy",
        "designation",
        "united",
        "state",
        "food",
        "drug",
        "alnylam",
        "pharmaceutical",
        "inc",
        "genzyme",
        "declined",
        "development",
        "commercialization",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}